LGND News Alert Ligand Pharmaceuticals Inc (LGND) 51.54 12/17/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Ligand Pharmaceuticals Inc (LGND) 51.54 $LGND

Ligand Pharmaceuticals: Investor Day Highlights The Big 6, All Undervalued Catalysts
Chris Katje - at Seeking Alpha - Mon Nov 24, 8:04AM CST

LGND: 51.54 (-0.70)

Ligand Provides Highlights from Today's Analyst Day Event
Business Wire - Tue Nov 18, 10:41AM CST
At an Analyst Day event held earlier today in New York City, Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) reviewed the financial leverage in its business model, revenue growth opportunities and its portfolio of partnered assets and unpartnered development programs, as well as its Captisol formulation technology and its financial outlook through 2017.
LGND: 51.54 (-0.70)

Ligand Pharmaceuticals Shares Up 17.2% Since SmarTrend's Buy Recommendation (LGND)
Comtex SmarTrend(R) - Tue Nov 18, 9:44AM CST
SmarTrend identified an Uptrend for Ligand Pharmaceuticals (NASDAQ:LGND) on October 17th, 2014 at $48.85. In approximately 1 month, Ligand Pharmaceuticals has returned 17.21% as of today's recent price of $57.25.
LGND: 51.54 (-0.70)

Ligand/Glaxo Seek EU Nod for Severe Aplastic Anemia Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 13, 4:00PM CST
Ligand Pharma (LGND) announced the submission of a Marketing Authorisation Application to the European Medicines Agency by its partner GlaxoSmithKline for Revolade.
LGND: 51.54 (-0.70), ILMN: 175.18 (-3.13), GSK: 41.92 (+0.62), CELG: 110.09 (-1.79)

Glaxo applies for Revolade label expansion in Europe
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 11:01AM CST

LGND: 51.54 (-0.70), GSK: 41.92 (+0.62)

Ligand Partner GlaxoSmithKline Announces EU Regulatory Submission for Severe Aplastic Anemia Indication for Revolade(TM) (eltrombopag)
Business Wire - Wed Nov 12, 8:15AM CST
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that its partner GlaxoSmithKline (GSK) plc reported the submission to the European Medicines Agency (EMA) of a variation to the Marketing Authorization for Revolade(TM) (eltrombopag), seeking an additional indication for the treatment of adult patients with severe aplastic anemia (SAA) who have had an insufficient response to immunosuppressive therapy (IST).
LGND: 51.54 (-0.70), GSK: 41.92 (+0.62)

Shares of LGND Up 13.9% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Tue Nov 11, 9:22AM CST
SmarTrend identified an Uptrend for Ligand Pharmaceuticals (NASDAQ:LGND) on October 17th, 2014 at $48.85. In approximately 4 weeks, Ligand Pharmaceuticals has returned 13.91% as of today's recent price of $55.64.
LGND: 51.54 (-0.70)

Merck presents data from its investigational HCV combo
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 8:37AM CST

JNJ: 102.76 (-1.20), GILD: 100.46 (-2.70), ACHN: 12.92 (+0.20), CNAT: 7.82 (-0.02), MRK: 56.80 (-0.15), LGND: 51.54 (-0.70), RGLS: 14.96 (-0.49), ABBV: 65.25 (-0.37), BMY: 57.69 (-0.86), ENTA: 41.14 (-1.97)

Gilead presents data from three HCV drug combo studies
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 8:05AM CST

JNJ: 102.76 (-1.20), GILD: 100.46 (-2.70), ACHN: 12.92 (+0.20), CNAT: 7.82 (-0.02), LGND: 51.54 (-0.70), RGLS: 14.96 (-0.49), ABBV: 65.25 (-0.37), BMY: 57.69 (-0.86), ENTA: 41.14 (-1.97)

Post Earnings Update: Ligand Pharmaceuticals Has Sunk 0.5% Lower in Past 2 Weeks (LGND)
Comtex SmarTrend(R) - Mon Nov 10, 11:52AM CST
When Ligand Pharmaceuticals (NASDAQ:LGND) reported earnings 14 days ago on October 27th, 2014, analysts, on average, expected the company to report earnings of $0.33 on sales of $14.9 million. The company actually reported EPS of $0.06 on sales of $15.0 million, missing EPS estimates by $0.27 and matching revenue estimates. Shares of Ligand Pharmaceuticals have slipped from $54.23 to $53.94, representing a loss of 0.5%, since the company reported earnings 14 days ago.
LGND: 51.54 (-0.70)

Merck triple therapy HCV candidate fails as a four-week regimen
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 6:49AM CST

JNJ: 102.76 (-1.20), GILD: 100.46 (-2.70), CNAT: 7.82 (-0.02), MRK: 56.80 (-0.15), LGND: 51.54 (-0.70), RGLS: 14.96 (-0.49), ABBV: 65.25 (-0.37), BMY: 57.69 (-0.86), ENTA: 41.14 (-1.97)

Bristol-Myers presents data on HCV Trio regimen
Seeking Alpha - at Seeking Alpha - Sun Nov 09, 5:04PM CST

JNJ: 102.76 (-1.20), GILD: 100.46 (-2.70), CNAT: 7.82 (-0.02), MRK: 56.80 (-0.15), LGND: 51.54 (-0.70), RGLS: 14.96 (-0.49), ABBV: 65.25 (-0.37), BMY: 57.69 (-0.86), ENTA: 41.14 (-1.97)

Bristol-Myers presents data on shorter regimen HCV drug combo
Seeking Alpha - at Seeking Alpha - Sun Nov 09, 4:37PM CST

JNJ: 102.76 (-1.20), GILD: 100.46 (-2.70), CNAT: 7.82 (-0.02), MRK: 56.80 (-0.15), LGND: 51.54 (-0.70), RGLS: 14.96 (-0.49), ABBV: 65.25 (-0.37), BMY: 57.69 (-0.86), ENTA: 41.14 (-1.97)

Achillion presents HCV data at The Liver Meeting
Seeking Alpha - at Seeking Alpha - Sun Nov 09, 4:06PM CST

JNJ: 102.76 (-1.20), GILD: 100.46 (-2.70), ACHN: 12.92 (+0.20), CNAT: 7.82 (-0.02), MRK: 56.80 (-0.15), LGND: 51.54 (-0.70), RGLS: 14.96 (-0.49), ABBV: 65.25 (-0.37), BMY: 57.69 (-0.86), ENTA: 41.14 (-1.97)

Ligand Pharmaceuticals' Shares Fall on Q3 Earnings Miss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 1:00PM CDT
Ligand Pharmaceuticals Incorporated (LGND) reported higher third-quarter earnings of 19 cents per share but fell short of the Zacks Consensus Estimate by 2 cents.
BIIB: 325.13 (-10.67), LGND: 51.54 (-0.70), AMGN: 159.44 (-0.16), GSK: 41.92 (+0.62)

Ligand Pharmaceuticals Has Rich A Valuation Now But Is Undervalued For Long Term Success
Chris Katje - at Seeking Alpha - Wed Oct 29, 10:34AM CDT

PFE: 30.67 (-0.19), AZN: 69.56 (-0.18), LGND: 51.54 (-0.70), AMGN: 159.44 (-0.16), GSK: 41.92 (+0.62)

Update: Ligand Posts Consecutive Earnings Beat
Trevor Lowenthal - at Seeking Alpha - Tue Oct 28, 3:21PM CDT

LGND: 51.54 (-0.70)

Ligand Pharmaceuticals' (LGND) CEO Steve Holmes on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Oct 27, 1:56PM CDT

LGND: 51.54 (-0.70)

Ligand Pharmaceuticals reaffirms full year 2014 guidance after Q3 results
Seeking Alpha - at Seeking Alpha - Mon Oct 27, 8:31AM CDT

LGND: 51.54 (-0.70)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Human Frontier Mission Puts AI Research on Display

Updated Category News Views 71

A laboratory notebook is about to become the real product in this AI experiment. Human Frontier Mission, or HFM, says it will launch globally on Nov. 24, opening a research program where domain specialists frame scientific and engineering problems while autonomous AI agents develop and test possible answers. The unusual bit is not merely handing models difficult work. It...

Continue Reading
Maryland Handgun Ban Suit Puts Ruger in Legal Crossfire

Updated Category News Views 135

A January Deadline With Real Commercial Teeth Maryland has turned a trigger-design dispute into a fresh legal and retail headache, and the clock is not polite about it. The National Shooting Sports Foundation filed suit against the state over S.B. 334, which is scheduled to take effect Jan. 1, 2027. The law bars sales of certain pistols with cruciform trigger bars,...

Continue Reading
Sitting, Lymph Flow, and a Supplement Maker's Pitch

Updated Category News Views 129

By late afternoon, a chair can feel like it has quietly won the argument against your legs. PureHealth Research is leaning into that familiar heavy, puffy-legged feeling with a reminder about lymphatic flow—and, naturally, an eight-ingredient supplement positioned alongside it. The broad message is sensible. The sales layer needs the usual healthy squint. Movement Does...

Continue Reading
Newegg’s GIGABYTE Event Is Brand Work, Not a Catalyst

Updated Category News Views 161

A 2,300-square-foot room can tell a retailer plenty about its tribe. On November 21, Newegg is turning its Diamond Bar Gamer Zone into the home base for GIGABYTE’s AORUS VS40 celebration, a free five-hour event marking the hardware maker’s 40th anniversary. There will be 1v1 VALORANT and League of Legends contests, demo stations, raffles, anniversary merchandise, food...

Continue Reading
Cottage Grove Tests Holiday Demand Across Lake Norman

Updated Category News Views 139

Flour and foot traffic make a pretty honest little scoreboard. Cottage Grove Bakery is putting itself in front of Lake Norman shoppers twice on Saturday, November 21, while also taking Thanksgiving orders and laying groundwork for 2027 workplace and school visits. This is not a public-company earnings story, and nobody should pretend a tray of scones is a quarterly...

Continue Reading
ModuleMD Takes Allergy EHR AI Beyond the Usual Hype Cycle

Updated Category News Views 210

Allergy Workflows Are Where This Has to Earn Its Keep Allergy clinics do not need another shiny dashboard clogging up a workstation. They need less typing, fewer handoffs, cleaner documentation, and fewer administrative chores slipping through the cracks while a packed day keeps moving. That is the practical lens for ModuleMD's ACAAI 2026 presentation in Phoenix: not...

Continue Reading
Kinross Lawsuit Puts Round Mountain Claims Under Fire

Updated Category News Views 101

A mine can swallow a rosy forecast faster than any spreadsheet admits. That is the ugly center of the proposed securities class action involving Kinross Gold: not merely that production guidance came down, but the allegation that investors were sold too much confidence before the operational reality at Round Mountain Phase S surfaced. NYSE:KGC dropped from $27.62 on...

Continue Reading
Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 28

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading
D-Wave Investors Face a December 15 Lead Plaintiff Clock

Updated Category News Views 162

August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...

Continue Reading
CCAPP Holiday Training Targets Seasonal Recovery Strain

Updated Category News Views 126

December cheer has a nasty habit of hiding the people barely holding themselves together. CCAPP’s upcoming virtual workshop, Hope for the Holidays: Understanding Depression, Stress & Resilience During the Holiday Season, takes that uncomfortable reality seriously rather than treating it like a seasonal footnote. For behavioral health workers supporting people in...

Continue Reading

Top 5 Most Recently Viewed Articles

Latham Group's Stock Target Rises: A Positive Outlook Ahead

Updated Category News Views 101

Stifel Holds a Positive View on Latham Group Inc. Stifel has recently reaffirmed its Buy rating for Latham Group Inc. (NASDAQ:SWIM) and bumped its price target to $7.00, up from the previous $6.80. This decision is fueled by upcoming investor meetings led by Latham Group's CEO, Scott Rajeski, and CFO, Oliver Gloe. These meetings aim to provide crucial insights into the...

Continue Reading
Keeper Delivers Undeniable Improvements in Account Management

Updated Category News Views 135

Keeper Introduces Instant Account Switching and Passkey Enhancements Keeper Security has recently unveiled a significant upgrade to its mobile applications and browser extension. This update is set to enhance user experience by introducing instant account switching and vital passkey features that make accessing different accounts faster than ever. Seamless Account...

Continue Reading
Sagard Real Estate Ventures into Growth with New Fund

Updated Category News Views 311

Sagard Real Estate Expands Portfolio with New Acquisition Sagard Real Estate, the firm formerly known as EverWest Real Estate Investors, is making waves in the real estate market with its recent acquisition of Vista Imperio. This strategic investment involves a 158-unit suburban garden-style multifamily property, marking a significant step forward for the company in its...

Continue Reading
Celebrating a Decade of Leadership in Complexity and Execution

Updated Category News Views 160

Reflecting on 10 Years of Team of Teams A decade ago, the revolutionary ideas presented in General Stanley McChrystal’s book, Team of Teams: New Rules of Engagement for a Complex World, emerged as a guiding light for leaders navigating complex environments. The principles outlined in this book have proven to be increasingly vital in today’s fast-paced world. Team of...

Continue Reading
Hakeem's Nomination Showcase for FinTech Excellence in 2024

Updated Category News Views 65

Hakeem Earns Recognition at the Singapore FinTech Festival Walee Group is thrilled to announce that its innovative product, Hakeem, has been nominated for the prestigious Singapore FinTech Festival - FinTech Excellence Awards. This accolade highlights the commitment of Walee Financial Services in developing solutions that enhance financial accessibility, particularly for...

Continue Reading